TCE2 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Celldex Therapeutics Inc

Watchlist Manager

Watchlist

Price: 36.02 EUR 2.24% Market Closed

Market Cap: €1.7B

C	Celldex Therapeutics Inc SWB:TCE2	US
	Telefonaktiebolaget LM Ericsson XETRA:ERCG	SE
	Bayan Resources Tbk PT IDX:BYAN	ID
	Volkswagen AG F:VOWA	DE
C	Canal+ SA OTC:CNALF	FR
I	Investec Ltd JSE:INL	ZA
M	Motorola Solutions Inc DUS:MTLA	US
Q	Q2 Holdings Inc F:0Q2	US
P	Prysmian SpA DUS:AEU	IT
	Scor SE PAR:SCR	FR

Profitability Summary

Celldex Therapeutics Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Low Gross Margin

Low 3Y Average Gross Margin

Negative Operating Margin

-206 220%

Negative 3Y Average Operating Margin

-24 324%

Declining Operating Margin

-3 720% > -206 220%

Negative Net Margin

-190 221%

Negative 3Y Average Net Margin

-22 255%

Declining Net Margin

-3 470% > -190 221%

Negative Free Cash Flow Margin

-153 231%

Negative 3Y Average Free Cash Flow Margin

-18 074%

Declining Free Cash Flow Margin

-3 506% > -153 231%

Negative ROE

-44%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-423%

Declining ROIC

-267% > -592%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.